CME Presentations

Refining the Maintenance Protocol for Advanced Ovarian Cancer


Presentations


Speakers

  • Ursula Matulonis, MD

    Ursula Matulonis, MD

    Ursula Matulonis, MD

    Chief, Division of Gynecologic Oncology

    Ursula A. Matulonis, MD, is chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School in Boston, Massachusetts. Her research focuses on developing targeted therapies for gynecologic malignancies, with a specific interest in ovarian and endometrial cancer. Dr Matulonis has led several PARP inhibitor and anti-angiogenic agent trials for ovarian cancer nationally and internationally. She serves on the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee, and the scientific advisory board for the Ovarian Cancer Research Alliance. Dr Matulonis has received the Dana-Farber Dennis Thompson Compassionate Care Scholar award and the Albany Medical College Alumni Association Distinguished Alumna Award in 2020.
  • Robert Wenham, MD, MS, FACOG, FACS

    Robert Wenham, MD, MS, FACOG, FACS

    Robert Wenham, MD, MS, FACOG, FACS

    Chair and Director of Research, Gynecologic Oncology Department

    Robert Wenham, MD, is chair of the Gynecologic Oncology Department at Moffitt Cancer Center, senior member of the Molecular Medicine Program, and professor of the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine in Tampa. He has a strong interest in research and is a principal investigator for numerous clinical trials to improve cancer care for women. Dr Wenham’s interests include novel therapeutics, complex cancer surgery, and medical education. He is a prior recipient of the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation. Dr Wenham received his medical degree from University of Texas Southwestern in Dallas.

CME Information

Refining the Maintenance Protocol for Advanced Ovarian Cancer


Global Logo PQH Logo

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Review currently approved maintenance therapy and evidence-based guidelines
  • Evaluate the role of PARP inhibitors and their efficacy in clinical subgroups
  • Assess the current and emerging PARP inhibitors for maintenance therapy, including efficacy data and novel dosing schedules
  • Interpret protocols to effectively manage adverse events, individualize dosing schedules, and improve patient outcomes
  • Appraise clinical data for selection of first-line maintenance treatment for patients with varying clinical profiles
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This educational activity is supported by an educational grant from GlaxoSmithKline.

DATE OF RELEASE/EXPIRATION

This activity was released on March 10, 2021 and is valid for 12 months. Requests for credit must be made no later than March 10, 2022.

TARGET AUDIENCE

The intended audience for this activity are gynecologic oncologists, medical oncologists, OB/GYNs, NPs, PAs, pharmacists, and other health care professionals involved in the care of patients with ovarian cancer.

STATEMENT OF NEED/PROGRAM OVERVIEW

The recent availability of PARP inhibitors as maintenance therapy in the first-line setting allows clinicians to offer improved treatment options to their patients with ovarian cancer. Join experts in the field as they examine the rationale for PARP inhibitors, the role of homologous recombination deficiency (HRD), as well as the efficacy and safety data that led to recent approvals for maintenance therapy. Case-based learning will exemplify the application of recent clinical-trial findings to treatment and patient selection, as well as side-effect management. Snapshots of patient preferences and strategies to improve communication with patients and other caregivers will be discussed to ensure care is optimized for every patient.

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Consulting Fee (e.g., Advisory Board): Merck, NextCure, Novartis
Honoraria: Advaxis
Robert M. Wenham, MD, MS, FACOG, FACS
Chair and Director of Research, Department of Gynecologic Oncology
Senior Member, Program of Chemical Biology and Molecular Medicine
Professor, Department of Interdisciplinary Oncology
University of South Florida
Consulting Fee (e.g., Advisory Board): Regeneron, GSK/Tesaro, AstraZeneca, Merck, Abbvie, Legend Biotech, Genentech, Seattle Genetics, Seagen, Mersana, Amgen, Clovis
Contracted Research: On Target Laboratories, Lion Biotechnologies, Merck, AstraZeneca, Morphotech, Millennium, Regeneron, Iovance, Tapimmune, Eisai, Abbvie, Anixia Biosciences
Speakers' Bureau: Genentech, Clovis
Stock Shareholder: Ovation Diagnostics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Jaimee Harris-Gold Nothing to disclose
Tariqa Ackbarali Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.